Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
about
Gastric biomarkers: a global reviewAdjuvant therapy for gastric cancer: what have we learned since INT0116?Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.CEP3 and CEP17 DNA probe potential in the genetic diagnosis and prognostic prediction of esophageal squamous cell cancer.Chemotherapy for advanced gastric cancer: review and update of current practices.Indirect comparison showed survival benefit from adjuvant chemoradiotherapy in completely resected gastric cancer with d2 lymphadenectomy.Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients.Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care.Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.The potential for targeting HER2 therapeutically in esophageal cancer - a grasp at straws?Resected gastric cancer with D2 dissection: advances in adjuvant chemoradiotherapy and radiotherapy techniques.Update on Gastroesophageal Adenocarcinoma Targeted Therapies.Advances in the Management of Gastric and Gastroesophageal Cancers.HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.Novel Targeted Therapies for Esophagogastric Cancer.Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer.Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer.Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer.HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.Progress of preoperative and postoperative radiotherapy in gastric cancer
P2860
Q26741859-1F748DAE-7C76-4623-91E0-DA67B14DE2F0Q27008675-EAD9614B-C8FC-44E9-96F1-B725F4154ACAQ30724810-5D5F3DE4-ABE6-439E-A956-9EF5E5D1FDCAQ35473187-5884A127-708A-4E4C-BA54-D9E5BB7A7142Q36358540-CF4DC747-AB22-4DFA-9668-3590E637148FQ36741053-E7F49B0A-AE64-4716-A58A-2E036BC676C5Q37046529-92F6791E-B2EA-4767-A2F7-50A5D56CAE78Q37250569-B46E4B36-8BA3-4630-9BE7-A50B888A5790Q37523508-215F8E7F-8490-449A-8BE9-2B4DDFF74C0FQ38134835-EA34BDB8-02CB-49F4-A915-D61229C08A0CQ38184380-41EB6082-333D-4BE7-8039-1E44AFAB3BA1Q38188598-25B60C07-392B-4B13-948E-66F6A90F305AQ38254375-D06DAAF4-28B1-4489-8429-1C95745E1E31Q38500269-7B657FCD-96FE-4C4D-A497-FB17F13C1648Q38684349-3D31643B-15DA-40D3-AC79-E8923C8E27DCQ38697255-ACD7A1ED-DC4B-4258-9DAB-EA4C554C9C8AQ39080349-49B26D1D-1510-4F41-8572-BDE58176C9B5Q39171565-018A3DBB-CB1E-4C6B-9A8F-BFF891C5A69CQ40619773-807C1F33-8024-42CF-BAB6-44649C20E720Q45241774-35AEAC11-B148-4A1E-A82F-FC4584A149A2Q47361762-CE0B5E85-0F29-4319-A14E-70A660B1EC12Q48103728-EE85F3BC-0472-4C62-AB95-DEA4987C4398Q53657591-8696CD0E-5BEF-409C-8A10-7C105E8669C4Q54323253-CCCCFE28-F53F-4C8D-A804-CE9E7E3E9693Q58743551-D92C8ACD-9CA9-48F2-94BE-D89EB965BCB7
P2860
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Assessment of HER2 gene amplif ...... -0116/SWOG9008 clinical trial.
@en
type
label
Assessment of HER2 gene amplif ...... -0116/SWOG9008 clinical trial.
@en
prefLabel
Assessment of HER2 gene amplif ...... -0116/SWOG9008 clinical trial.
@en
P2093
P2860
P356
P1433
P1476
Assessment of HER2 gene amplif ...... -0116/SWOG9008 clinical trial.
@en
P2093
C D Blanke
H M Gundacker
J Benedetti
J C Baranda
J S Macdonald
M A Gordon
P2860
P304
P356
10.1093/ANNONC/MDT106
P577
2013-03-22T00:00:00Z